TRIM26 and metabolic dysfunction-associated steatohepatitis: In a set of mice models exhibiting non-alcoholic steatohepatitis (NASH), the targeted removal of TRIM26 specifically in hepatocytes resulted in a substantial increase in hepatic steatosis, liver inflammation, and hepatofibrosis.